卵巢癌术前静脉血栓栓塞症发生的危险因素
Risk Factors for Preoperative Venous Thromboembolism of Ovarian Cancer
DOI: 10.12677/ACM.2023.134811, PDF,    科研立项经费支持
作者: 于建龙, 高悦文, 李洪琦*:山东大学医学院,山东 济南;山东省立医院妇产科,山东 济南;李长忠:山东省立医院妇产科,山东 济南;北京大学深圳医院妇产科,广东 深圳
关键词: 静脉血栓栓塞症卵巢癌危险因素Venous Thromboembolism Ovarian Cancer Risk Factors
摘要: 目的:讨论卵巢恶性肿瘤患者在手术前发生静脉血栓栓塞的危险因素。方法:搜集2018年1月1日至2021年3月21日在山东省立医院妇科进行手术的卵巢癌患者共178例,包括45例术前发生静脉血栓的患者和133例术前未发生静脉血栓的患者,回顾性分析卵巢癌在术前发生静脉血栓栓塞症的危险因素。结果:单因素分析提示肿瘤直径、D-二聚体、病理分期、CA125和病理类型的差异有统计学意义(P < 0.05);血小板、年龄、腹水、心血管疾病史的差异无统计学意义(P > 0.05)。多因素分析提示年龄、D-二聚体、病理类型和肿瘤直径是卵巢癌患者在术前发生静脉血栓栓塞症的独立危险因素。ROC曲线分析提示可以联合应用肿瘤分期、D-二聚体和病理类型预测卵巢癌患者术前静脉血栓栓塞症的发生,并且具有一定的诊断效能。结论:肿瘤直径、D-二聚体、病理分期、CA125和病理类型是卵巢癌患者在术前发生静脉血栓栓塞的危险因素,其中D-二聚体、肿瘤分期和病理类型对于手术前的卵巢癌患者及早发现血栓形成具有临床诊断意义。
Abstract: Objective: To discuss the risk factors for the occurrence of venous thromboembolism in patients with ovarian cancer before surgery. Methods: A total of 178 ovarian cancer patients who received surgery at the Department of Gynecology, Shandong Provincial Hospital from January 1, 2018 to March 21, 2021, including 45 patients with preoperative venous thrombosis and 133 patients without preoperative venous thrombosis, were collected to retrospectively analyze the risk factors for the occurrence of venous thromboembolism in ovarian cancer before surgery. Results: Univari-ate analysis suggested statistically significant differences in tumor diameter, D-dimer, pathological stage, CA125 and pathological type (P < 0.05); no statistically significant differences in platelets, age, ascites, and history of cardiovascular disease (P > 0.05). Multifactorial analysis suggested that age, D-dimer, pathology type and tumor diameter were independent risk factors for preoperative venous thromboembolism in ovarian cancer patients, and ROC curve analysis suggested that tumor stage, D-dimer and pathology type could be combined to predict the occurrence of preoperative ve-nous thromboembolism in ovarian cancer patients with certain diagnostic efficacy. Conclusions: Tumor diameter, D-dimer, pathological stage, CA125 and pathological type are risk factors for pre-operative venous thromboembolism in ovarian cancer patients, among which D-dimer, tumor stage and pathological type have clinical diagnostic significance for early detection of thrombosis in ovar-ian cancer patients before surgery.
文章引用:于建龙, 高悦文, 李长忠, 李洪琦. 卵巢癌术前静脉血栓栓塞症发生的危险因素[J]. 临床医学进展, 2023, 13(4): 5746-5754. https://doi.org/10.12677/ACM.2023.134811

参考文献

[1] Khorana, A.A., et al. (2006) Thromboembolism in Hospitalized Neutropenic Cancer Patients. Journal of Clinical Oncol-ogy, 24, 484-490. [Google Scholar] [CrossRef
[2] Korte, W. (2008) Cancer and Thrombosis: An Increasingly Important Association. Supportive Care in Cancer, 16, 223- 228. [Google Scholar] [CrossRef] [PubMed]
[3] Sørensen, H.T., Mellemkjaer, L., Olsen, J.H. and Baron, J.A. (2000) Prognosis of Cancers Associated with Venous Thromboembolism. The New England Journal of Medicine, 343, 1846-1850. [Google Scholar] [CrossRef
[4] Glassman, D., Bateman, N.W., Lee, S., et al. (2022) Molec-ular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers (Basel), 14, 1496. [Google Scholar] [CrossRef] [PubMed]
[5] Strøm Kahr, H., Christiansen, O.B., Juul Riddersholm, S., et al. (2021) The Timing of Venous Thromboembolism in Ovarian Cancer Patients: A Nationwide Danish Cohort Study. Journal of Thrombosis and Haemostasis, 19, 992-1000. [Google Scholar] [CrossRef] [PubMed]
[6] Satoh, T., Oki, A., Uno, K., et al. (2007) High Incidence of Silent Venous Thromboembolism before Treatment in Ovarian Cancer. British Journal of Cancer, 97, 1053-1057. [Google Scholar] [CrossRef] [PubMed]
[7] 张佳佳, 张易. 卵巢癌伴肺栓塞患者术前溶栓结合新辅助化疗的护理[J]. 上海护理, 2016, 16(6): 59-61.
[8] 中华医学会外科学分会血管外科学组. 深静脉血栓形成的诊断和治疗指南(第三版) [J]. 中华普通外科杂志, 2017, 32(9): 807-812. [Google Scholar] [CrossRef
[9] Lee, A.Y. and Levine, M.N. (2003) Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation, 107, I17-I21. [Google Scholar] [CrossRef
[10] Dunbar, A., Bolton, K.L., Devlin, S.M., et al. (2021) Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors. Blood, 137, 2103-2113. [Google Scholar] [CrossRef] [PubMed]
[11] Zhu, C., Xu, Z., Zhang, T., et al. (2021) Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. Journal of Cancer, 12, 2295-2316. [Google Scholar] [CrossRef] [PubMed]
[12] Ye, S., Yang, J., Cao, D., et al. (2015) Characteristic and Prog-nostic Implication of Venous Thromboembolism in Ovarian Clear Cell Carcinoma: A 12-Year Retrospective Study. PLOS ONE, 10, e0121818. [Google Scholar] [CrossRef] [PubMed]
[13] Abu Saadeh, F., Norris, L., O’Toole, S., et al. (2013) Tumour Expresion of Tissue Factor and Tissue Factor Pathway Inhibitor in Ovarian Cancer-Relationship with Venous Throm-bosis Risk. Thrombosis Research, 132, 627-634. [Google Scholar] [CrossRef] [PubMed]
[14] Anglesio, M.S., George, J., Kulbe, H., et al. (2011) IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17, 2538-2548. [Google Scholar] [CrossRef
[15] Gi, T., Yamashita, A., Aman, M., et al. (2021) Tissue Fac-tor Expression and Tumor-Infiltrating T Lymphocytes in Ovarian Carcinomas and Their Association with Venous Thromboembolism. Pathology International, 71, 261-266. [Google Scholar] [CrossRef] [PubMed]
[16] Matsuo, K., Hasegawa, K., Yoshino, K., et al. (2015) Venous Thrombo-embolism, Interleukin-6 and Survival Outcomes in Patients with Advanced Ovarian Clear Cell Carcinoma. European Journal of Cancer, 51, 1978-1988. [Google Scholar] [CrossRef] [PubMed]
[17] Zhou, Q., Zhu, C., Shen, Z., et al. (2020) Incidence and Potential Predictors of Thromboembolic Events in Epithelial Ovarian Carcinoma Patients during Perioperative Period. European Journal of Surgical Oncology, 46, 855-861. [Google Scholar] [CrossRef] [PubMed]
[18] Khorana, A.A., Kuderer, N.M., Culakova, E., et al. (2008) Devel-opment and Validation of a Predictive Model for Chemotherapy-Associated Thrombosis. Blood, 111, 4902-4907. [Google Scholar] [CrossRef] [PubMed]
[19] Carrier, M., Le Gal, G., Bates, S.M. anderson, D.R. and Wells, P.S. (2008) D-Dimer Testing Is Useful to Exclude Deep Vein Thrombosis in Elderly Outpatients. Journal of Thrombosis and Haemostasis, 6, 1072-1076. [Google Scholar] [CrossRef] [PubMed]
[20] Habu, Y., Mitsuhashi, A., Hanawa, S., et al. (2021) High Prevalence of Pulmonary Embolism Prior to Cancer Therapies in Patients with Ovarian and Endometrial Cancers Detect-ed by Contrast-Enhanced CT Using D-Dimer as an Index. Journal of Surgical Oncology, 124, 106-114. [Google Scholar] [CrossRef] [PubMed]
[21] Swier, N. and Versteeg, H.H. (2017) Reciprocal Links between Venous Thromboembolism, Coagulation Factors and Ovarian Cancer Progression. Thrombosis Research, 150, 8-18. [Google Scholar] [CrossRef] [PubMed]
[22] Marinho, A., Fernandes, G., Carvalho, T., et al. (2008) Non-tuberculous Mycobacteria in Non-AIDS Patients. Revista Portuguesa de Pneumologia, 14, 323-337. [Google Scholar] [CrossRef
[23] Heit, J.A., Ashrani, A., Crusan, D.J., et al. (2017) Reasons for the Persistent Incidence of Venous Thromboembolism. Thrombosis and Haemostasis, 117, 390-400. [Google Scholar] [CrossRef
[24] Kodama, J., Seki, N., Fukushima, C., et al. (2013) Elevated Preopera-tive Plasma D-Dimer Levels and the Incidence of Venous Thromboembolism in Japanese Females with Gynecological Cancer. Oncology Letters, 5, 299-304. [Google Scholar] [CrossRef] [PubMed]
[25] Liang, S., Tang, W., Ye, S., et al. (2020) Incidence and Risk Factors of Preoperative Venous Thromboembolism and Pulmonary Embolism in Patients with Ovarian Cancer. Thrombosis Re-search, 190, 129-134. [Google Scholar] [CrossRef] [PubMed]
[26] Chokshi, S.K., Gaughan, J.P. and Krill, L. (2022) Incidence and Patient Characteristics of Venous Thromboembolism during Neoadjuvant Chemotherapy for Ovarian Cancer. Jour-nal of Thrombosis and Thrombolysis, 53, 202-207. [Google Scholar] [CrossRef] [PubMed]
[27] Greco, P.S., Bazzi, A.A., McLean, K., et al. (2017) Incidence and Timing of Thromboembolic Events in Patients with Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Ob-stetrics & Gynecology, 129, 979-985. [Google Scholar] [CrossRef
[28] Magnus, N., Garnier, D. and Rak, J. (2010) Oncogenic Epidermal Growth Factor Receptor Up-Regulates Multiple Elements of the Tissue Factor Signaling Pathway in Human Glioma Cells. Blood, 116, 815-818. [Google Scholar] [CrossRef] [PubMed]
[29] Falanga, A., Panova-Noeva, M. and Russo, L. (2009) Pro-coagulant Mechanisms in Tumour Cells. Best Practice & Research Clinical Haematology, 22, 49-60. [Google Scholar] [CrossRef] [PubMed]